Current Affairs · · GS2 · Social Justice

Centre plans 30% trade-margin cap on all non-scheduled cancer drugs

The Centre plans to cap the trade margin on all non-scheduled anti-cancer medicines at 30% of the maximum retail price. The pricing regulator found average mark-ups of about 170% between distributor and patient. A 2019 pilot on 42 cancer drugs cut some prices by up to 85%, but savings will depend on careful monitoring.

Event date:

REq1
  1. Context1 / 5
    • The Union government plans to cap the trade margin on all non-scheduled anti-cancer drugs at 30% of the maximum retail price (MRP).
    • The plan is reported to cover branded, generic, domestic, imported, patented and off-patent cancer medicines.
    • The National Pharmaceutical Pricing Authority (NPPA) found average trade mark-ups of about 170%, with some reaching 700%.
    • An expert committee under the Directorate General of Health Services will finalise which medicines are covered.
  2. Key concepts2 / 5

    1. What is a trade margin?

    The gap between the price at which a company sells to distributors, the price to stockist, and the MRP paid by the patient. It covers the earnings of wholesalers and retailers. Capping it at 30% of the MRP means the MRP can be at most about 1.43 times the stockist price, which is a mark-up of about 43%.

    2. Scheduled and non-scheduled drugs

    India regulates the two types of medicine differently.

    • Scheduled drugs. Medicines in the National List of Essential Medicines, listed in the DPCO schedule. NPPA fixes a ceiling price.
    • Non-scheduled drugs. All other medicines. Companies set prices, and the annual MRP increase is limited to 10%.

    3. What powers does the NPPA use?

    The NPPA, set up in 1997 under the Department of Pharmaceuticals, enforces the Drugs (Prices Control) Order, 2013. Paragraph 19 lets it fix the price of any drug, scheduled or not, in extraordinary circumstances and in the public interest.

  3. Key highlights3 / 5
    • In February 2019, the NPPA used Paragraph 19 to cap trade margins at 30% on 42 non-scheduled anti-cancer drugs, as a pilot.
    • The cap covered 72 formulations and 355 brands, with revised prices from 8 March 2019.
    • Prices of 105 brands fell, some by as much as 85%. The NPPA estimated savings of at least ₹200 crore a year for patients.
    • The new plan would extend this approach to all non-scheduled cancer drugs.
  4. Note4 / 5

    Why it matters, and the risks

    • Out-of-pocket spending. Cancer treatment is long and costly, and much of it is paid by families from their own pockets. Lower retail prices can directly reduce that burden.
    • The limits of the tool. A margin cap controls the mark-up after the factory gate. It does not fix the manufacturer's base price, which can still be high for patented drugs.
    • The risk of cost-shifting. Firms could raise the stockist price, or hospitals could add charges elsewhere in the bill, eroding the benefit.
    • Supply concerns. Lower margins may reduce the incentive for distributors to stock some drugs in smaller towns.
  5. Way forward5 / 5
    • Publish the list of covered drugs and the price calculations.
    • Monitor actual hospital bills, not only MRPs, since many cancer drugs are bought through hospitals.
    • Require disclosure of procurement prices across the supply chain.
    • Promote generics and biosimilars, to increase competition.
    • Expand public procurement for cancer care, through government hospitals and Jan Aushadhi stores.

Sources

Syllabus

PaperSubjectSub-topic
GS2Social JusticeIssues relating to health; government policies and interventions
GS3EconomyPharmaceutical sector regulation; price control
PrelimsEconomyNPPA; the Drugs (Prices Control) Order, 2013; scheduled and non-scheduled drugs; trade margin

Topics

Human Development and Sustainable DevelopmentIndustryGovernanceNon-Constitutional BodiesHealth

Practice questions

  1. With reference to drug price regulation in India, consider the following statements: 1. The NPPA fixes ceiling prices of scheduled drugs under the Drugs (Prices Control) Order, 2013. 2. Paragraph 19 of the DPCO allows the government to fix prices of non-scheduled drugs in the public interest. 3. The NPPA works under the Ministry of Health and Family Welfare. Which of the statements given above are correct?

    1. 1 and 2 only
    2. 2 and 3 only
    3. 1 and 3 only
    4. 1, 2 and 3
    Show answer

    Answer: A. Statements 1 and 2 are correct. Statement 3 is wrong: the NPPA works under the Department of Pharmaceuticals, which is part of the Ministry of Chemicals and Fertilizers, not the Ministry of Health and Family Welfare. Paragraph 19 is the provision that lets it reach drugs outside the schedule, which is what the 2019 cap relied on.

    Difficulty: medium · statement

  2. "Trade margin" in pharmaceutical pricing refers to which one of the following?

    1. The manufacturer's profit over its production cost
    2. The difference between the price to stockist and the maximum retail price
    3. The GST charged on medicines
    4. The import duty on active ingredients
    Show answer

    Answer: B. The trade margin is the mark-up earned along the distribution chain, between the price at which the company sells to a stockist and the price the patient pays. It is distinct from the manufacturer’s own margin, which is why capping it leaves the base price untouched.

    Difficulty: easy · statement

Mains practice

Answer-writing practice on this article. Attempt it first, then open the hints.

  1. GS2 · 250 words

    Can capping trade margins make cancer treatment affordable? Examine its benefits and limits.

    Show hints
    1. Establish the problem through out-of-pocket spending on a long and costly illness, and through the scale of the mark-ups the regulator found.
    2. Explain the instrument precisely: it caps the distribution mark-up between the stockist price and the printed price, and nothing else.
    3. Use the 2019 pilot as evidence that it works, with prices of many brands falling and estimated annual savings for patients.
    4. Set out the limits, since the manufacturer’s base price is untouched and remains the binding constraint for patented medicines.
    5. Conclude on leakage and supply: firms may raise the stockist price or hospitals shift charges, and thin margins may thin stocking in smaller towns, so monitoring of actual bills matters as much as the cap.